UK report recommends better planning for phase I drug trialsBMJ 2007; 334 doi: https://doi.org/10.1136/bmj.39153.352234.DB (Published 15 March 2007) Cite this as: BMJ 2007;334:551
- Susan Mayor
The first trials of new drugs in humans should be planned much more carefully, with the same clarity of purpose, design, and analysis as for studies supporting drug licensing, a report published this week recommends.
The report, published by a working party of the Royal Statistical Society, was prompted by the TGN1412 drug trial last year in which six healthy volunteers experienced severe immune reactions (BMJ 2005;332:683, doi: 10.1136/bmj.332.7543.683). It found that “the trial design was not well suited to its objectives of testing the safety and tolerability of the drug.”
Stephen Senn, professor of statistics at the University of Glasgow …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial